The success of Sildenafil initially fueled a surge for major pharmaceutical companies, but recent changes present a murky outlook for those considering a stake. Off-patent alternatives are eroding revenue, and https://anitardrm032517.theisblog.com/41603846/sildenafil-and-big-pharma-a-precarious-play